---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-220788"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2025-09-26T23:59:59+00:00"
generated_at: "2026-05-17T05:33:22.409583+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# Atossa Therapeutics posts updated corporate presentation; no specific financial details provided

## Summary
- Filed as Exhibit 99.1 on September 26, 2025, but presentation content not included in this filing text.
- No new financial figures, pipeline milestones, or guidance changes are extractable from the available text.
- Ticker ATOS; company is a clinical-stage biotech focused on breast cancer treatments.
- Investors would need to view the actual presentation to assess any material updates.

## SEC filing metadata
- accession: 0001193125-25-220788
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2025-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000119312525220788/0001193125-25-220788-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000119312525220788/atos-20250926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-220788
- JSON: https://secwatch.observer/filing/0001193125-25-220788.json
- Plain text: https://secwatch.observer/filing/0001193125-25-220788.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.